Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Tuspetinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aptose Publishes Preclinical on Tuspetinib’s Action in AML Cells
    Aptose Publishes Preclinical on Tuspetinib’s Action in AML Cells

    12 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/12/2996333/35575/en/Aptose-Announces-Publication-of-Preclinical-Data-in-AACR-Journal-Demonstrating-Tuspetinib-s-Unique-Mechanism-of-Action-and-Synthetic-Lethality-on-AML-Cells-When-Combined-with-Venet.html

    GLOBENEWSWIRE
    12 Dec 2024
    Share Share
    Aptose Data Supports Tuspetinib Triple Drug Therapy for AML
    Aptose Data Supports Tuspetinib Triple Drug Therapy for AML

    09 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/09/2993973/35575/en/Aptose-Clinical-Data-Featured-in-Poster-Presentation-at-the-2024-ASH-Annual-Meeting-Support-Tuspetinib-Triple-Drug-Therapy-for-Newly-Diagnosed-AML.html

    GLOBENEWSWIRE
    09 Dec 2024
    Share Share
    Aptose Receives $10M From Hanmi; Negotiating Future Collaboration
    Aptose Receives $10M From Hanmi; Negotiating Future Collaboration

    30 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/30/2938722/35575/en/Aptose-Receives-10-Million-Through-a-Facility-Agreement-with-Hanmi-Negotiating-Future-Collaboration-Agreement-with-Hanmi-to-Jointly-Develop-Tuspetinib.html

    GLOBENEWSWIRE
    30 Aug 2024
    Share Share
    Aptose Reports Results for the Second Quarter 2024
    Aptose Reports Results for the Second Quarter 2024

    08 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/08/2927451/35575/en/Aptose-Reports-Results-for-the-Second-Quarter-2024.html

    GLOBENEWSWIRE
    08 Aug 2024
    Share Share
    Aptose Presents Tuspetinib Findings At EHA 2024
    Aptose Presents Tuspetinib Findings At EHA 2024

    14 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/14/2898921/35575/en/Aptose-Presents-Tuspetinib-TUS-Clinical-and-Preclinical-Findings-at-European-Hematology-Association-EHA-2024-Hybrid-Congress.html

    GLOBENEWSWIRE
    14 Jun 2024
    Share Share
    Aptose Tuspetinib Data Featured in Oral Presentation
    Aptose Tuspetinib Data Featured in Oral Presentation

    09 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/09/2793449/35575/en/Aptose-Tuspetinib-Clinical-Data-Featured-in-Oral-Presentation-at-the-2023-ASH-Annual-Meeting.html

    GLOBENEWSWIRE
    09 Dec 2023
    Share Share